CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines.

in Clinical cancer research : an official journal of the American Association for Cancer Research by Amy M McCord, Muhammad Jamal, Eli S Williams, Kevin Camphausen, Philip J Tofilon

TLDR

  • The study looked at how sensitive different types of brain cancer cells called CD133+ TSCs are to radiation. The researchers found that these cells are more sensitive to radiation than other types of brain cancer cells. They also found that the way these cells respond to radiation is different from the way other types of brain cancer cells respond. This information could help doctors develop new treatments for brain cancer that specifically target these sensitive cells.

Abstract

CD133+ glioblastoma tumor stem-like cells (TSC) have been defined as radioresistant. However, although previously classified relative to CD133- cells, the radiosensitivity of CD133+ TSCs with respect to the standard glioblastoma model, established glioma cell lines, has not been determined. Therefore, to better understand the radioresponse of this cancer stem cell, we have used established cell lines as a framework for defining their in vitro radioresponse. The intrinsic radiosensitivity of CD133+ TSC cultures and established glioma cell lines was determined by clonogenic assay. The TSCs and established cell lines were also compared in terms of DNA double-strand break (DSB) repair capacity and cell cycle checkpoint activation. Based on clonogenic analysis, each of the six TSC cultures evaluated was more sensitive to radiation than the established glioma cell lines. Consistent with increased radiosensitivity, the DSB repair capacity as defined by neutral comet assay and gammaH2AX and Rad51 foci was significantly reduced in TSCs compared with the cell lines. Although G2 checkpoint activation was intact, in contrast to the cell lines, DNA synthesis was not inhibited in TSCs after irradiation, indicating the absence of the intra-S-phase checkpoint. These data indicate that the mechanisms through which CD133+ TSCs respond to radiation are significantly different from those of the traditional glioblastoma in vitro model, established glioma cell lines. If TSCs play a critical role in glioblastoma treatment response, then such differences are likely to be of consequence in the development and testing of radiosensitizing agents.

Overview

  • The study aims to determine the intrinsic radiosensitivity of CD133+ TSCs compared to established glioma cell lines. The methodology used includes clonogenic assay, DNA double-strand break (DSB) repair capacity, and cell cycle checkpoint activation. The primary objective is to understand the radioresponse of CD133+ TSCs and compare it to the standard glioblastoma model. The study finds that each of the six TSC cultures evaluated is more sensitive to radiation than the established glioma cell lines, with reduced DSB repair capacity and absence of the intra-S-phase checkpoint in TSCs. The findings suggest that the mechanisms through which CD133+ TSCs respond to radiation are significantly different from those of the traditional glioblastoma in vitro model, established glioma cell lines.

Comparative Analysis & Findings

  • The study compares the outcomes observed under different experimental conditions or interventions, specifically the intrinsic radiosensitivity of CD133+ TSCs and established glioma cell lines. The results show that each of the six TSC cultures evaluated is more sensitive to radiation than the established glioma cell lines. The DSB repair capacity and cell cycle checkpoint activation were also significantly reduced in TSCs compared with the cell lines. These findings suggest that the mechanisms through which CD133+ TSCs respond to radiation are significantly different from those of the traditional glioblastoma in vitro model, established glioma cell lines.

Implications and Future Directions

  • The study's findings have significant implications for the field of research and clinical practice. The differences in radioresponse between CD133+ TSCs and established glioma cell lines suggest that the mechanisms through which CD133+ TSCs respond to radiation are significantly different from those of the traditional glioblastoma in vitro model. This knowledge could be used to develop and test radiosensitizing agents specifically targeting CD133+ TSCs. However, the study has limitations, such as the small sample size and the need for further validation in vivo. Future research could explore the role of CD133+ TSCs in glioblastoma treatment response and develop novel radiosensitizing agents specifically targeting these cells.